EUVIMEDEUVIMED entdecken
Crossref

Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID ‐19 in clinical practice during the Omicron ( BA .1 and BA .2) pandemic

Kan Kikuchi, Masaomi Nangaku, Munekazu Ryuzaki, Tomoyuki Yamakawa, Yoshihiro Ota, Norio Hanafusa, Ken Sakai, Yoshihiko Kanno, Ryoichi Ando, Toshio Shinoda, Shu Wakino, Hidetomo Nakamoto und 3 weitere

Therapeutic Apheresis and Dialysis · 2023

DOI: 10.1111/1744-9987.14033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, 2023. Verfasst von Kan Kikuchi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Shimoochiai Clinic, Tokyo, Japan. Hauptthemen laut MEDLINE: COVID-19, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In the present study, the efficacy of sotrovimab and molnupiravir in dialysis patients with COVID‐19 was investigated using a registry of COVID‐19 in Japanese dialysis patients.

Methods

Dialysis patients with confirmed SARS‐CoV‐2 during the COVID‐19 (Omicron BA.1 and BA.2) pandemic were analyzed. Patients were classified into four treatment groups: molnupiravir monotherapy (molnupiravir group), sotrovimab monotherapy (sotrovimab group), molnupiravir and sotrovimab combination therapy (combination group), and no antiviral therapy (control group). The mortality rates in the four groups were compared.

Results

A total of 1480 patients were included. The mortality of the molnupiravir, sotrovimab, and combination groups were significantly improved compared to the control group ( p < 0.001). Multivariate analysis indicated that antiviral therapy improves the survival of dialysis patients with COVID‐19 (hazard ratio was 0.184 for molnupiravir, 0.389 for sotrovimab, and 0.254 for combination groups, respectively).

Conclusion

Sotrovimab showed efficacy in Omicron BA.1 but attenuated in BA.2. Molnupiravir also showed efficacy in BA.2, suggesting administration of molnupiravir would be important.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antiviral AgentsHumansEast Asian PeoplePandemicsRenal DialysisSARS-CoV-2COVID-19 Drug TreatmentCytidineHydroxylaminesAntibodies, NeutralizingAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

COVID-19SARS-CoV-2dialysis patientsmolnupiravirsotrovimab

Substanzen

Antiviral AgentsmolnupiravirCytidineHydroxylaminessotrovimabAntibodies, NeutralizingAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Nephrology, Shimoochiai Clinic, Tokyo, Japan.
  • Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
  • Department of Nephrology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.
  • Kidney Center, Shirasagi Hospital, Osaka, Japan.
  • Nagoya Memorial Hospital, Nagoya, Japan.
  • Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan.

ORCID-Profile: Tadao Akizawa

Zitieren

APA

Kikuchi, K., Nangaku, M., Ryuzaki, M., Yamakawa, T., Ota, Y., Hanafusa, N., Sakai, K., Kanno, Y., Ando, R., Shinoda, T., Wakino, S., Nakamoto, H., Takemoto, Y., Akizawa, T., & COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephro… (2023). Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID ‐19 in clinical practice during the Omicron ( BA .1 and BA .2) pandemic. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14033

Vancouver

Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Ota Y, Hanafusa N, et al. Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID ‐19 in clinical practice during the Omicron ( BA .1 and BA .2) pandemic. Therapeutic Apheresis and Dialysis. 2023. doi:10.1111/1744-9987.14033

BibTeX
@article{Kikuchi2023,
  author = {Kikuchi, Kan and Nangaku, Masaomi and Ryuzaki, Munekazu and Yamakawa, Tomoyuki and Ota, Yoshihiro and Hanafusa, Norio and Sakai, Ken and Kanno, Yoshihiko and Ando, Ryoichi and Shinoda, Toshio and Wakino, Shu and Nakamoto, Hidetomo and Takemoto, Yoshiaki and Akizawa, Tadao and COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephro…, COVID-19 Task Force Committee of the Japanese Association of Dialysis Physicians, the Japanese Society for Dialysis Therapy, and the Japanese Society of Nephro…},
  title = {Efficacy of molnupiravir and sotrovimab in Japanese dialysis patients with COVID ‐19 in clinical practice during the Omicron ( BA .1 and BA .2) pandemic},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2023},
  doi = {10.1111/1744-9987.14033}
}
Kostenlos starten →